Bertrand Coiffier1. 1. Hospices Civils de Lyon, Lyon, France. Bertrand.coiffier@chu-lyon.fr
Abstract
PURPOSE OF REVIEW: This paper reviews the improvement in the treatment of patients with diffuse large B cell lymphoma. RECENT FINDINGS: The outcome in these patients has become better with longer survival because of two major developments: (1) increasing the dose of active drugs and shortening the time between cycles, resulting in dose-dense or dose-intense regimens, and (2) combining rituximab with chemotherapy. Both strategies have been associated with higher response rates, longer event-free survival, and longer overall survival, particularly in patients without adverse prognostic parameters. A combination of both is currently being tested for these poor-risk patients. SUMMARY: Although improvement has been made in low-risk patients, much work has to be done for patients with high-risk lymphoma. It may come with a better definition of genetic abnormalities specifically associated with refractoriness to chemotherapy.
PURPOSE OF REVIEW: This paper reviews the improvement in the treatment of patients with diffuse large B cell lymphoma. RECENT FINDINGS: The outcome in these patients has become better with longer survival because of two major developments: (1) increasing the dose of active drugs and shortening the time between cycles, resulting in dose-dense or dose-intense regimens, and (2) combining rituximab with chemotherapy. Both strategies have been associated with higher response rates, longer event-free survival, and longer overall survival, particularly in patients without adverse prognostic parameters. A combination of both is currently being tested for these poor-risk patients. SUMMARY: Although improvement has been made in low-risk patients, much work has to be done for patients with high-risk lymphoma. It may come with a better definition of genetic abnormalities specifically associated with refractoriness to chemotherapy.
Authors: Lan V Pham; Lingchen Fu; Archito T Tamayo; Carlos Bueso-Ramos; Elias Drakos; Francisco Vega; L Jeffrey Medeiros; Richard J Ford Journal: Blood Date: 2010-10-01 Impact factor: 22.113
Authors: D Pore; J Bodo; A Danda; D Yan; J G Phillips; D Lindner; B T Hill; M R Smith; E D Hsi; N Gupta Journal: Leukemia Date: 2015-03-24 Impact factor: 11.528
Authors: Jiehua Zhou; Katrin Tiemann; Pritsana Chomchan; Jessica Alluin; Piotr Swiderski; John Burnett; Xizhe Zhang; Stephen Forman; Robert Chen; John Rossi Journal: Nucleic Acids Res Date: 2013-03-06 Impact factor: 16.971